Argent BioPharma Limited Stock Australian S.E.
Stocks
MXC
AU000000MXC6
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0360 AUD | +2.86% |
|
0.00% | -48.57% |
| 25/05 | Argent Biopharma enters long term Aquiol licensing and supply agreement | RE |
| 06/05 | Argent BioPharma Ltd Announces Board Changes | CI |
| Market Cap | 4M 2.8M 2.43M 2.24M 2.1M 3.92M 268M 26.7M 10.34M 129M 10.5M 10.28M 449M | P/E Ratio 2024 |
-0.63x | P/E Ratio 2025 | -0.26x |
|---|---|---|---|---|---|
| Enterprise Value | 11.26M 7.88M 6.84M 6.3M 5.91M 11.03M 754M 75.18M 29.11M 364M 29.58M 28.94M 1.26B | EV / Sales 2024 |
25.4x | EV / Sales 2025 | 72.6x |
| Free-Float |
44.79% | Yield 2024 * |
-
| Yield 2025 | - |
| Current month | -10.00% | ||
| 3 months | -18.18% | ||
| 6 months | -47.83% | ||
| Current year | -48.57% |
| 1 week | 0.04 |  | 0.04 |
| 1 month | 0.03 | | 0.04 |
| 3 years | 0.03 | | 6 |
| 5 years | 0.03 | | 67 |
| 10 years | 0.03 | | 130 |
| Manager | Title | Age | Since |
|---|---|---|---|
Roby Zomer
CEO | Chief Executive Officer | 46 | 12/05/2017 |
Yifat Steuer
COO | Chief Operating Officer | 55 | 04/10/2022 |
Nadya Lisovoder
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Roby Zomer
CHM | Chairman | 46 | 06/05/2026 |
Daniel Robinson
BRD | Director/Board Member | - | 01/12/2023 |
Andrew Chapman
BRD | Director/Board Member | - | 06/05/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.86% | 0.00% | -59.55% | -99.40% | 2.73M | |
| +1.65% | +6.42% | +53.16% | +109.62% | 54.82B | |
| +0.03% | -1.80% | +49.57% | +43.94% | 43.27B | |
| +2.98% | -1.08% | -15.96% | -19.28% | 21.79B | |
| +5.61% | -7.79% | -1.26% | +396.13% | 19.92B | |
| +0.81% | -8.38% | +12.77% | -33.24% | 15.67B | |
| +0.53% | +2.08% | +8.89% | -40.13% | 15.26B | |
| +1.38% | +1.70% | +28.84% | +179.62% | 13.22B | |
| -5.27% | +3.89% | +90.88% | +208.02% | 11.58B | |
| -1.74% | -1.05% | +12.88% | - | 11.94B | |
| Average | +0.68% | -0.58% | +18.02% | +82.81% | 23.05B | |
| Weighted average by Cap. | +1.10% | +1.16% | +31.86% | +97.32% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 891K 623K 541K 499K 467K 873K 59.68M 5.95M 2.3M 28.77M 2.34M 2.29M 100M | 181K 126K 110K 101K 94.67K 177K 12.09M 1.21M 467K 5.83M 474K 464K 20.27M |
| Net income | -17.53M -12.26M -10.64M -9.81M -9.19M -17.17M -1.17B -117M -45.3M -566M -46.03M -45.04M -1.97B | -17.84M -12.48M -10.83M -9.98M -9.36M -17.48M -1.2B -119M -46.11M -576M -46.86M -45.85M -2B |
| Net Debt | 9.02M 6.31M 5.48M 5.05M 4.73M 8.84M 604M 60.22M 23.31M 291M 23.69M 23.18M 1.01B | 7.26M 5.08M 4.41M 4.06M 3.81M 7.11M 486M 48.48M 18.77M 234M 19.07M 18.66M 815M |
Employees
-
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/06/26 | 0.0360 $ | +2.86% | 8,473 |
| 10/06/26 | 0.0350 $ | -2.78% | 58 |
| 09/06/26 | 0.0360 $ | 0.00% | 27,862 |
| 04/06/26 | 0.0360 $ | -5.26% | 431,590 |
| 03/06/26 | 0.0380 $ | 0.00% | 819 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RGT Stock
- MXC Stock
Select your edition
All financial news and data tailored to specific country editions
